Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Shared Decision Making in Hemophilia Patient CareRelease Date:Quality Improvement Rare Disease China Optimizing HRRm Testing and Workflow Integration in mCSPCRelease Date:Quality Improvement, Research Oncology Canada Driving Timely Biomarker Testing to Optimize Treatment Decisions for Colorectal Cancer Patients Across CanadaRelease Date:Partner: Colorectal Cancer Canada (CCC)Quality Improvement, Research Oncology Canada Optimizing Disease Management to Improve Alopecia Areata Quality of CareRelease Date:Quality Improvement Inflammation & Immunology China Providing Appropriate Medical Care for IBD PatientsRelease Date:Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD)Quality Improvement Inflammation & Immunology Japan Fostering Educational Initiatives for ALK+ Metastatic Non-Small Cell Lung Cancer(mNSCLC) Tyrosine Kinase Inhibitors(TKI) TherapyRelease Date:Education Oncology Canada 2026 Headache Medicine Fellowship - USRelease Date:Fellowship Internal Medicine USA Advances in Migraine ManagementRelease Date:Education Internal Medicine USA Real-World Evidence of SUL-DUR on Special Populations with CRAB InfectionRelease Date:Research Inflammation & Immunology China Optimizing Atopic Dermatitis Quality of Care and Best Practice at Local LevelRelease Date:Quality Improvement Inflammation & Immunology China Addressing HCP Knowledge Gaps in Baseline Assessments for Adults with Ulcerative Colitis Starting S1P Receptor Modulator TherapyRelease Date:Education Inflammation & Immunology USA Use of AI to Improve Speed/Precision of Treatment Selection & Clinical Management for Patients w/ Invasive Mold InfectionsRelease Date:Education Hospital Australia, China, France, Germany, Italy, Korea, Spain, Taiwan, United Kingdom Quality improvement strategies to enhance quality of life in ALK-positive lung cancer patientsRelease Date:Quality Improvement Oncology Spain Maintenance Therapy in HER2+ Metastatic Breast Cancer (MBC)Release Date:Education Oncology USA Efforts to Improve Quality of Migraine CareRelease Date:Partner: The Japanese Headache SocietyQuality Improvement Internal Medicine Japan Enhancing HCP Education in Adult Vaccination against Respiratory InfectionsRelease Date:Education Vaccines Austria, Belgium, Greece, Ireland, Luxembourg, Portugal, Switzerland Migraine and Women’s HealthQuality Improvement, Research Internal Medicine USA Real World Evidence on clinical outcomes with Aztreonam-Avibactam (ATM-AVI)Release Date:Research Inflammation & Immunology All Improving Health Outcomes in Patients with ATTR-CM Through the Development of a Shared Decision-Making Tool (Decision Aid)Release Date:Research Rare Disease USA Capacity Building for Clinical Trials in Sickle Cell Disease (SCD) - Education for Healthcare ProfessionalsRelease Date:Education Rare Disease USA Prostate Cancer: Best Practices for Combining Targeted Therapies in mPCRelease Date:Education Oncology USA Transthyretin Cardiac Amyloidosis FellowshipRelease Date:Research Rare Disease USA Optimizing Adult Vaccination Ecosystem in IndiaRelease Date:Quality Improvement Vaccines India Evidence Based Safety Contextualization of JAK inhibitors in the Treatment of Moderate to Severe Atopic DermatitisRelease Date:Education Inflammation & Immunology China, France, Germany, Italy, Japan, Korea, Spain, USA Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple MyelomaRelease Date:Research Oncology Spain Optimizing Clinical Care Delivery for Patients with Multiple Myeloma Receiving Bispecific AntibodiesRelease Date:Quality Improvement Oncology All Enhancing HCP Education in Maternal VaccinationRelease Date:Education Vaccines Saudi Arabia Diagnosis and Treatment of Cancer CachexiaRelease Date:Education Oncology All Evidence-Based Education on the Potential Impact of a Generic JAK Inhibitor on the Management of Rheumatologic DiseasesRelease Date:Education Inflammation & Immunology USA B-cell Maturation Antigen (BCMA) Bi-Specific Antibodies (BsAbs) in Relapsed/Refractory Multiple Myeloma (RRMM)Release Date:Education Oncology USA Education on Mechanism of Action of JAK3 and TEC Family Kinase Role in Alopecia AreataRelease Date:Education Inflammation & Immunology USA 2026 Hemophilia Fellowship – United StatesRelease Date:Fellowship Rare Disease All Pediatric Pneumococcal Disease and Serotype Distribution: Surveillance Studies in Saudi ArabiaRelease Date:Research Vaccines Saudi Arabia Optimising Ulcerative Colitis Care: Bridging Knowledge Gaps, Integrating Biomarker-Based Strategies, and Advancing EquityRelease Date:Education Inflammation & Immunology Australia Surveillance of Pneumococcal Disease Serotype Distribution in Pediatric and Adult Pneumococcal Disease in TürkiyeRelease Date:Research Vaccines Turkey Surveillance of Pneumococcal Disease Serotype Distribution in Pediatric and Adult Pneumococcal Disease in TürkiyeRelease Date:Research Vaccines Turkey Title Grant Type Focus Area Country Application Due Date Life-Long Learning and Implementation of Education in Pain Associated with Osteoarthritis (Europe EFIC)Quality Improvement Internal Medicine Albania, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, France, Metropolitan, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Moldova, Republic of, Netherlands, Norway, Poland, Portugal, Romania, Russia, San Marino, Slovakia (Slovak Republic), Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom Use of Biosimilar Agents in Inflammatory ConditionsRelease Date:Education Inflammation & Immunology USA Diagnosis of Invasive Fungal InfectionsRelease Date:Education Hospital Afghanistan, Albania, Algeria, American Samoa, Andorra, Angola, Anguilla, Antarctica, Antigua and Barbuda, Argentina, Armenia, Aruba, Australia, Austria, Azerbaijan, Bahamas, Bahrain, Bangladesh, Barbados, Belarus, Belgium, Belize, Benin, Bermuda, Bhutan, Bolivia, Bosnia and Herzegovina, Botswana, Bouvet Island, Brazil, British Indian Ocean Territory, Brunei Darussalam, Bulgaria, Burkina Faso, Burundi, Cambodia, Cameroon, Canada, Cape Verde, Cayman Islands, Central African Republic, Chad, Chile, China, Christmas Island, Cocos (Keeling) Islands, Colombia, Comoros, Congo, Congo, The Democratic Republic, Cook Islands, Costa Rica, Cote D'ivoire, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Djibouti, Dominica, Dominican Republic, East Timor, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Estonia, Ethiopia, Falkland Islands (Malvinas), Faroe Islands, Fiji, Finland, France, France, Metropolitan, French Guiana, French Polynesia, French Southern Territories, Gabon, Gambia, Georgia, Germany, Ghana, Gibraltar, Greece, Greenland, Grenada, Guadeloupe, Guam, Guatemala, Guinea, Guinea-bissau, Guyana, Haiti, Heard and Mc Donald Islands, Holy See (Vatican City State), Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iran (Islamic Republic of), Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kiribati, Korea, Korea, Democratic People's Rep, Kuwait, Kyrgyzstan, Lao People's Democratic Republ, Latvia, Lebanon, Lesotho, Liberia, Libyan Arab Jamahiriya, Liechtenstein, Lithuania, Luxembourg, Macau, Macedonia, The Former Yugoslav, Madagascar, Malawi, Malaysia, Maldives, Mali, Malta, Marshall Islands, Martinique, Mauritania, Mauritius, Mayotte, Mexico, Micronesia, Federated States o, Moldova, Republic of, Monaco, Mongolia, Montserrat, Morocco, Mozambique, Myanmar, Namibia, Nauru, Nepal, Netherlands, Netherlands Antilles, New Caledonia, New Zealand, Nicaragua, Niger, Nigeria, Niue, Norfolk Island, Northern Mariana Islands, Norway, Oman, Pakistan, Palau, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Pitcairn, Poland, Portugal, Puerto Rico, Qatar, Reunion, Romania, Russia, Russian Federation, Rwanda, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadin, Samoa, San Marino, Sao Tome and Principe, Saudi Arabia, Senegal, Seychelles, Sierra Leone, Singapore, Slovakia (Slovak Republic), Slovenia, Solomon Islands, Somalia, South Africa, South Georgia and the South Sa, Spain, Sri Lanka, St. Helena, St. Pierre and Miquelon, Sudan, Suriname, Svalbard and Jan Mayen Islands, Swaziland, Sweden, Switzerland, Syrian Arab Republic, Taiwan, Tajikistan, Tanzania, United Republic of, Thailand, Togo, Tokelau, Tonga, Trinidad and Tobago, Tunisia, Turkey, Turkmenistan, Turks and Caicos Islands, Tuvalu, Uganda, Ukraine, United Arab Emirates, United Kingdom, United States Minor Outlying I, Uruguay, Uzbekistan, Vanuatu, Venezuela, Vietnam, Virgin Islands (British), Virgin Islands (U.S.), Wallis and Futuna Islands, Western Sahara, Yemen, Yugoslavia, Zambia, Zimbabwe Adoption of Biosimilars in OncologyRelease Date:Partner:The National Comprehensive Cancer Network® (NCCN)
Research Oncology USA Improving Disparities in Rheumatoid Arthritis Health Care in Post COVID-19 Era in memory of Cinzia CurialeRelease Date:Education Inflammation & Immunology Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Liechtenstein, Luxembourg, Netherlands, Portugal, Spain, Sweden, Switzerland, United Kingdom Management of Non-Communicable Diseases (NCD) for Health Care ProvidersRelease Date:Education Internal Medicine Albania, Andorra, Armenia, Austria, Azerbaijan, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Holy See (Vatican City State), Hungary, Iceland, Ireland, Italy, Japan, Kazakhstan, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, The Former Yugoslav, Malta, Moldova, Republic of, Monaco, Netherlands, Norway, Poland, Portugal, Romania, Russia, San Marino, Slovakia (Slovak Republic), Slovenia, Spain, Sweden, Switzerland, Turkey, USA, Ukraine, United Kingdom Continuity of Care: Education for Rheumatology PatientsRelease Date:Education Inflammation & Immunology USA Assessment of on-time immunization coverage in children under 2 years of age in CanadaRelease Date:Research Vaccines Canada Optimal Early Therapy Management in CMLRelease Date:Quality Improvement Oncology Canada, USA Addressing Knowledge Gaps in Growth Hormone DeficiencyRelease Date:Education Rare Disease USA Addressing Racial Disparities in Cancer CareQuality Improvement Oncology USA Telehealth in Postmenopausal Patient CareRelease Date:Education Internal Medicine USA Implementation of Telemedicine in Inflammatory Conditions: A Quality Improvement RFPRelease Date:Quality Improvement Inflammation & Immunology Canada, USA ADVANCE: Global Awards for Advancing Chronic Pain ResearchResearch Internal Medicine All Improving Disparities in Ulcerative Colitis Health Care in Post COVID-19 EraRelease Date:Quality Improvement Inflammation & Immunology United Kingdom New Guidelines for Immuno-therapy in Urothelial Carcinoma (UC)Release Date:Partner: Merck KGaA Darmstadt, Germany and EMD SeronoEducation Oncology France, Germany, Italy, Spain, USA, United Kingdom Emerging Mechanisms of Action in the Treatment of Moderate-to-Severe Alopecia AreataRelease Date:Education Inflammation & Immunology USA PARP-inhibitor Combination Treatments in Prostate CancerRelease Date:Education Oncology All Remote Mentoring Programs in RCCRelease Date:Education Oncology USA Quality of Care Improvement in Metastatic Breast Cancer Patients (Europe)Release Date:Partner: The Sharing Progress in Cancer Care (SPCC)Quality Improvement Oncology All Identifying and Diagnosing polyarticular Juvenile Idiopathic Arthritis (pJIA)Release Date:Education Inflammation & Immunology Canada, USA Metastatic Breast Cancer Patient Education: Navigating Treatment & Decision MakingRelease Date:Education Oncology Canada, USA NSCLC Oncogene Driver Considerations in Testing & TreatmentRelease Date:Education Oncology USA Unmet Need and Burden of Disease in Moderate-to-Severe Alopecia AreataRelease Date:Education Inflammation & Immunology France, Germany Emerging Mechanisms of Action in the Treatment of Moderate-to-Severe Atopic DermatitisRelease Date:Education Inflammation & Immunology All Pharmacist Education in Biosimilars (Western Europe, Canada, Japan)Release Date:Education Oncology All Biosimilars in Hematologic Malignancies & Supportive CareRelease Date:Education Oncology All The Burden and Origins of Co-Infections in COVID-19 Pneumonia (Europe)Release Date:Education Hospital All Needs Assessment – Early Therapy Management with CDK 4/6 Inhibitors in Metastatic Breast CancerRelease Date:Education Oncology USA Advances in Atopic Dermatitis for Advanced PractitionersRelease Date:Education Inflammation & Immunology USA 2020 RD US- Next Generation PET Imaging for ATTR-CMResearch Rare Disease USA Cardiac Transthyretin Amyloid (ATTR) Fellowship Competitive Grant ProgramRelease Date:Partner: International Society of AmyloidosisFellowship Rare Disease All Management of Moderate-to-Severe Atopic Dermatitis for Dermatologists and AllergistsRelease Date:Education Inflammation & Immunology USA Pfizer and Mayo Clinic/Global Bridges–Providing Access to Learning Resources for Tobacco Dependence TreatmentEducation Internal Medicine China, Malaysia, Taiwan, Thailand 4th Quality Improvement initiatives optimizing AF and VTE management in CanadaQuality Improvement Internal Medicine Canada 2021 Rheumatology Competitive Grant ProgramRelease Date:Research Inflammation & Immunology USA 2021 Ulcerative Colitis Competitive Grant ProgramRelease Date:Research Inflammation & Immunology USA Adoption of Biosimilars in OncologyRelease Date:Quality Improvement Oncology Canada 2021 Global Hemophilia ASPIRERelease Date:Research Rare Disease All Inflammatory and Immune-Mediated Dermatologic DisordersRelease Date:Research Inflammation & Immunology USA Advances in Atopic Dermatitis & Alopecia Areata for Community Pharmacists & Managed Care Health Care ProfessionalsRelease Date:Education Inflammation & Immunology USA Understanding Residual Cardiovascular Risk Related to Triglyceride-Rich Remnant LipoproteinsRelease Date:Education Internal Medicine All Call for Independent Medical Education Grant Applications Oncology – Prostate CancerEducation Oncology USA I&I REALE 2021 RhEumatoid Arthritis Italian ReaL World ExperienceRelease Date:Research Inflammation & Immunology Italy 2021 Inflammatory Bowel Disease (IBD) FellowshipRelease Date:Fellowship Inflammation & Immunology USA Inflammatory and Immune-Mediated Dermatologic Disorders (Global excluding U.S.)Release Date:Research Inflammation & Immunology All 2021 Rheumatology FellowshipRelease Date:Fellowship Inflammation & Immunology USA 2021 Fellowship for Inflammatory Dermatological DiseasesRelease Date:Fellowship Inflammation & Immunology USA